Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Parecoxib
Drug ID BADD_D01674
Description Parecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States. A letter of non-approval for parecoxib was issued by the FDA in 2005.
Indications and Usage Used for short term perioperative pain control.
Marketing Status approved
ATC Code M01AH04
DrugBank ID DB08439
KEGG ID D03716
MeSH ID C409945
PubChem ID 119828
TTD Drug ID D05UWI
NDC Product Code Not Available
UNII 9TUW81Y3CE
Synonyms parecoxib | N-(((5-methyl-3-phenylisoxazol-4-yl)-phenyl)sulfonyl)propanamide | N-(((Me-P)-P)S)P | parecoxib sodium | N-(((5-methyl-3-phenylisoxazol-4-yl)-phenyl)sulfonyl)propanamine, sodium salt | Dynastat
Chemical Information
Molecular Formula C19H18N2O4S
CAS Registry Number 198470-84-7
SMILES CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory failure22.02.06.002; 14.01.04.003--
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Stevens-Johnson syndrome23.03.01.007; 10.01.01.045; 12.03.01.014; 11.07.01.005--
Swelling08.01.03.015--Not Available
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Toxic epidermal necrolysis11.07.01.006; 10.01.01.006; 23.03.01.008; 12.03.01.015--
Ulcer08.03.06.001--Not Available
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vomiting07.01.07.003--
Wound infection12.01.08.012; 11.01.08.010--
Anaemia postoperative12.02.05.032; 01.03.02.014--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Post procedural complication12.02.05.018--Not Available
Angiopathy24.03.02.007--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Alveolar osteitis07.09.01.006; 15.02.04.017; 11.01.04.010--Not Available
Gastrointestinal sounds abnormal07.01.01.002--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages